Second Sight Medical Products

Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company was founded on May 22,2003 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Paris, France, March 09, 2021 – Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Second Sight Medical Products, Inc. (« Second Sight ») (Nasdaq: EYES) continues under the terms announced to the market on January 6, 2021.

Continuation of the business combination project between Pixium Vision et Second Sight Medical Products

Second Sight Medical Products Inc (NASDAQ: EYES) shares have soared above 723% over the previous two trading sessions with the stock touching an intraday high of $14.83 on Monday. The shares registered a spike of nearly 103% as of Monday's closing.

Why Second Sight Medical Products Has Skyrocketed 723% In 2 Trading Sessions

Shares of Second Sight Medical Products Inc. soared 104.2% on heavy volume in midday trading Monday, bringing its two-day gain to 728.7%, after the Food and Drug Administration approved the company's Argus 2s Retinal Prosthesis System for the treatment of retinitis pigmentosa (RP). The stock paced all gainers on major U.S. exchanges, and was the most actively traded, as trading volume swelled to 222.6 million shares, compared with the full-day average of 26.5 million shares.

Second Sight Medical stock skyrockets 8-fold in 2 days after FDA approves retinal prosthesis system

Second Sight Medical Products (EYES) stock just can't stop soaring higher following approval from the FDA on Friday for one of its devices. The post EYES Stock: 12 Things for Second Sight Medical Investors to Know as Shares Keep Rocketing appeared first on InvestorPlace.

EYES Stock: 12 Things for Second Sight Medical Investors to Know as Shares Keep Rocketing

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) is trading at over 55% pre-market. This is why it happened.

EYES Stock Price Increases Over 55% Pre-Market: Why It Happened

Shares of Second Sight Medical Products shot up by nearly tenfold Friday after the Food and Drug Administration cleared for use a visual prosthesis system that the company has redesigned. The company said its Argus 2s Retinal Prosthesis System was approved initially for use in combination with previously implanted Argus II systems to treat retinitis pigmentosa.

Second Sight Medical Products soars 592% after the FDA approves its visual prosthetic system (EYES)

Second Sight (EYES) stock is soaring higher Friday after announcing approval from the FDA for its Argus 2s Retinal Prosthesis System. The post EYES Stock: The Big FDA News That Has Second Sight Shares Soaring appeared first on InvestorPlace.

EYES Stock: The Big FDA News That Has Second Sight Shares Soaring

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by over 40% pre-market. This is why it happened.

EYES Stock Price Increases Over 40% Pre-Market: Why It Happened

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced U.S. Food and Drug Administration (FDA) has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the trea

Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at UCLA Medical Center (“UCLA”). The study, which includes four participants at UCLA and two participants at Baylor College of Medicine (“

Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA

Aptevo Therapeutics

Blink Charging

Energy Focus

SG Blocks

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major three indices.

Top Stocks To Short As Nasdaq Sets New Intraday Record

Brighthouse Financial

Jaguar Health

RumbleON

Soleno Therapeutics

If you're wondering how markets are still surging in light of record-breaking coronavirus cases, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology has you covered with the Top Shorts today.

Top Stocks To Short As Dow Passes 300 Points

BIO-key Int.

Cocrystal Pharma

EyePoint Pharmaceuticals

Recro Pharma

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Top Stocks To Short As Dow Jumps Amid Coronavirus Spikes

Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Second Sight Medical Products' (EYES) CEO Will McGuire on Q4 2019 Results - Earnings Call Transcript

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 4.08% and -40.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Second Sight Medical Products (EYES) Reports Q4 Loss, Misses Revenue Estimates

Will Second Sight Medical Products (EYES) Report Negative Q4 Earnings? What You Should Know

Second Sight Medical Products, Inc's (EYES) CEO Will McGuire on Q3 2019 Results - Earnings Call Transcript

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and -49.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates

Will Second Sight Medical Products (EYES) Report Negative Earnings Next Week? What You Should Know

Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Second Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q2 2019 Results - Earnings Call Transcript

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and 183.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Second Sight Medical Products Stock (EYES)